Prospects for the Use of ATR Inhibitors to Treat Cancer
- PMID: 27713304
- PMCID: PMC4033983
- DOI: 10.3390/ph3051311
Prospects for the Use of ATR Inhibitors to Treat Cancer
Abstract
ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.
Keywords: ATM; ATR; Chk1; Replication checkpoint; chemotherapy.
Figures




Similar articles
-
Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.Cancer Lett. 2016 Dec 1;383(1):41-52. doi: 10.1016/j.canlet.2016.09.024. Epub 2016 Sep 28. Cancer Lett. 2016. PMID: 27693461
-
The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.Adv Cancer Res. 2010;108:73-112. doi: 10.1016/B978-0-12-380888-2.00003-0. Adv Cancer Res. 2010. PMID: 21034966 Review.
-
ATR/CHK1 inhibitors and cancer therapy.Radiother Oncol. 2018 Mar;126(3):450-464. doi: 10.1016/j.radonc.2017.09.043. Epub 2017 Oct 18. Radiother Oncol. 2018. PMID: 29054375 Free PMC article. Review.
-
Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.Cancer Res. 2006 Sep 1;66(17):8672-9. doi: 10.1158/0008-5472.CAN-05-4443. Cancer Res. 2006. PMID: 16951182
-
The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.J Virol. 2018 Feb 26;92(6):e01884-17. doi: 10.1128/JVI.01884-17. Print 2018 Mar 15. J Virol. 2018. PMID: 29263259 Free PMC article.
Cited by
-
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.Cancer Biol Ther. 2012 Sep;13(11):1072-81. doi: 10.4161/cbt.21093. Epub 2012 Jul 24. Cancer Biol Ther. 2012. PMID: 22825331 Free PMC article.
-
CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer.Comput Struct Biotechnol J. 2021 Apr 18;19:2384-2397. doi: 10.1016/j.csbj.2021.04.036. eCollection 2021. Comput Struct Biotechnol J. 2021. PMID: 34025931 Free PMC article. Review.
-
Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.Neoplasia. 2018 Nov;20(11):1135-1143. doi: 10.1016/j.neo.2018.08.009. Epub 2018 Sep 23. Neoplasia. 2018. PMID: 30257222 Free PMC article.
-
Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.Cancer Res. 2014 Dec 15;74(24):7534-45. doi: 10.1158/0008-5472.CAN-14-2650. Epub 2014 Oct 21. Cancer Res. 2014. PMID: 25336189 Free PMC article.
-
3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer.Oncol Lett. 2018 Jun;15(6):8878-8884. doi: 10.3892/ol.2018.8367. Epub 2018 Mar 28. Oncol Lett. 2018. PMID: 29805624 Free PMC article.
References
-
- Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408:433–439. - PubMed
-
- Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316–323. - PubMed
-
- Keith C.T., Schreiber S.L. PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints. Science. 1995;270:50–51. - PubMed
-
- Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006;7:606–619. - PubMed
-
- Bosotti R., Isacchi A., Sonnhammer E.L. FAT: a novel domain in PIK-related kinases. Trends Biochem. Sci. 2000;25:225–227. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous